Skip to content

Posts by Douglas Middleton Dahl, MD

  • At the 2019 AUA Annual Conference, urologists from Mass General discussed research findings, novel treatment approaches and advances in clinical care, including...

  • The American Urological Association (AUA) is hosting its Annual Meeting in Chicago, IL from May 3-6, 2019. Specialists from the Massachusetts General Hospital Department of Urology will present on leading research and innovative treatment approaches. Mass General doctors will participate in over 20 different sessions covering the full spectrum of urologic care, including bladder, prostate, urologic oncology and more.

  • Researchers at Massachusetts General Hospital have developed a digital assay that quantifies prostate tumor cells in blood samples, and the results predict response to the drug abiraterone in metastatic cancer or early dissemination of localized disease.

  • Robotic surgery can decrease blood loss and patient pain, lead to a shorter recovery time than a traditional laparoscopic approach, and offers surgeons a shorter learning curve.

  • The optimal timing of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy is controversial. Mass General researchers aim to clear up the controversy by reviewing patients who were treated in the modern era of PSA testing.

  • Physicians at Massachusetts General Hospital are in the early stages of testing a novel regimen for patients with muscle-invasive urothelial bladder cancer who are medically unfit for radical cystectomy or platinum-based radiosensitizing chemotherapy.


Dr. Dahl graduated from Princeton University with honors where he majored in molecular biology. His thesis project was to study genes related to the development of cancer. He then attended medical school at Yale University, where he graduated in the top 10% of his class as recognized by the AOA honor medical society. His internship and residency training were at Harvard. He spent two years in general surgery training at the Brigham and Women's hospital, Boston Children's hospital, and West Roxbury V.A. Hospital. He then completed four years of training in Urology in the Harvard Longwood Area program in Urology. This program included training at the above-mentioned hospitals and the Beth Israel Hospital of Boston. He served as a research fellow at the Dana Farber Cancer Institute, where he studied the genetics of prostate cancer. He then moved to the University of Massachusetts Medical Center, where he was the head of urologic laparoscopic surgery. It was there that many firsts in New England took place: The first laparoscopic kidney donor surgery for transplant, and the first laparoscopic radical prostatectomy surgery.

In 2001, he was recruited to start the program in laparoscopic and minimally invasive surgery at Massachusetts General Hospital. His contributions have been recognized by the hospital, where he serves as Director of Robotic Surgery and Chief of the Division of Urologic Oncology. He has also been honored by Harvard Medical School with the title of Associate Professor of Surgery.